DGAP-News

MOLOGEN AG: Presentation on IMPACT study at ESMO Symposium on Immuno-Oncology

DGAP-News: MOLOGEN AG / Key word(s): Study results
MOLOGEN AG: Presentation on IMPACT study at ESMO Symposium on
Immuno-Oncology

17.11.2014 / 08:00

---------------------------------------------------------------------

MOLOGEN AG: Presentation on IMPACT study at ESMO Symposium on
Immuno-Oncology

Berlin, November 17, 2014 - MOLOGEN, a biotechnology company, announced
today that data on long-term treated metastatic colorectal cancer patients
from the IMPACT study will be presented at the ESMO Symposium on
Immuno-Oncology 2014. The Symposium will take place on November 21-22 in
Geneva.

IMPACT was a randomized placebo-controlled phase II trial with the cancer
immune therapy MGN1703 in metastatic colorectal cancer.

Prof. Dr. Werner Scheithauer, Clinical Division of Oncology, Department of
Medicine I, University Hospital in Vienna, Austria, one of the coordinating
investigators of the IMPACT trial, will present the data in his lecture at
the "Best Abstracts Session".

Abstract details:
Title: Long-term maintenance therapy with the TLR-9 agonist MGN1703 in a
subgroup of metastatic colorectal cancer patients from the IMPACT study.

Best Abstracts Session: November 21, 2014 at 5.25 pm - 6.45 pm.

The abstract will be published in the ESMO Symposium on Immuno-Oncology
2014 Abstract Book, a supplement to the official ESMO journal Annals of
Oncology.

For more information on the ESMO please visit ESMO's website:
http://www.esmo.org/Conferences/Immuno-Oncology-2014.

For more information on the IMPACT trial please visit
www.clinicaltrials.gov.

About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal
Carcinoma with Disease Control after Initial First-line Therapy) was a
phase II, randomized, placebo-controlled, double-blind, multicenter
clinical study aiming to determine the efficacy of MGN1703 as switch
maintenance therapy following first-line chemotherapy with or without
bevacizumab in patients with metastatic colorectal cancer.

Patients included in the IMPACT study had stabilization, or partial or
complete remission of their disease after receiving first-line therapy for
4.5 to 6 months. The Patients were randomized to receive either MGN1703 or
placebo twice per week. The treatment was continued until tumor progression
was observed.

The primary endpoint of the study was to determine progression-free
survival of the patients. Secondary study endpoints included overall
survival, progression-free survival from start of induction therapy,